

# Satya Prakash

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4742361/publications.pdf>

Version: 2024-02-01

164  
papers

10,476  
citations

38720

50  
h-index

36008

97  
g-index

168  
all docs

168  
docs citations

168  
times ranked

18280  
citing authors

#	ARTICLE	IF	CITATIONS
1	Microencapsulated Multifunctionalized Graphene Oxide Equipped with Chloroquine for Efficient and Sustained siRNA Delivery. <i>BioMed Research International</i> , 2022, 2022, 1-16.	0.9	4
2	Baculoviruses in Gene Therapy and Personalized Medicine. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 115-132.	3.0	8
3	Albumin Nanoparticle Formulation for Heart-Targeted Drug Delivery: In Vivo Assessment of Congestive Heart Failure. <i>Pharmaceuticals</i> , 2021, 14, 697.	1.7	7
4	Synthesis and characterization of peptide conjugated human serum albumin nanoparticles for targeted cardiac uptake and drug delivery. <i>PLoS ONE</i> , 2021, 16, e0254305.	1.1	6
5	Microbiome and Human Aging: Probiotic and Prebiotic Potentials in Longevity, Skin Health and Cellular Senescence. <i>Nutrients</i> , 2021, 13, 4550.	1.7	41
6	Polymeric Microspheres Containing Human Vocal Fold Fibroblasts for Vocal Fold Regeneration. <i>Laryngoscope</i> , 2020, 131, 1828-1834.	1.1	4
7	Microbial Medicine: Prebiotic and Probiotic Functional Foods to Target Obesity and Metabolic Syndrome. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2890.	1.8	133
8	The Microbiome and Alzheimer's Disease: Potential and Limitations of Prebiotic, Synbiotic, and Probiotic Formulations. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 537847.	2.0	47
9	A novel synbiotic delays Alzheimer's disease onset via combinatorial gut-brain-axis signaling in <i>Drosophila melanogaster</i> . <i>PLoS ONE</i> , 2019, 14, e0214985.	1.1	61
10	Ferulic Acid Produced by <i>Lactobacillus fermentum</i> Influences Developmental Growth Through a dTOR-Mediated Mechanism. <i>Molecular Biotechnology</i> , 2019, 61, 1-11.	1.3	21
11	Artificial cell microcapsules containing live bacterial cells and activated charcoal for managing renal failure creatinine: preparation and <i>in-vitro</i> analysis. <i>The EuroBiotech Journal</i> , 2019, 3, 190-196.	0.5	0
12	Polyethylene glycol and octa-arginine dual-functionalized nanographene oxide: an optimization for efficient nucleic acid delivery. <i>Biomaterials Science</i> , 2018, 6, 1636-1650.	2.6	35
13	A novel polyphenolic prebiotic and probiotic formulation have synergistic effects on the gut microbiota influencing <i>Drosophila melanogaster</i> physiology. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 441-455.	1.9	44
14	Novel Milrinone Nanoformulation for Use in Cardiovascular Diseases: Preparation and <i>in Vitro</i> Characterization. <i>Molecular Pharmaceutics</i> , 2018, 15, 2489-2502.	2.3	17
15	Longevity extension in <i>Drosophila</i> through gut-brain communication. <i>Scientific Reports</i> , 2018, 8, 8362.	1.6	72
16	Effect of artificial cell miniaturization on urea degradation by immobilized <i>E. coli</i> DH5 $\alpha$ (pKAU17). <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 766-775.	1.9	1
17	Novel microencapsulated probiotic blend for use in metabolic syndrome: design and <i>in-vivo</i> analysis. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 116-124.	1.9	18
18	Microbial Biotransformation of a Polyphenol-Rich Potato Extract Affects Antioxidant Capacity in a Simulated Gastrointestinal Model. <i>Antioxidants</i> , 2018, 7, 43.	2.2	2

#	ARTICLE	IF	CITATIONS
19	Absorption and Metabolism of Phenolics from Digests of Polyphenol-Rich Potato Extracts Using the Caco-2/HepG2 Co-Culture System. <i>Foods</i> , 2018, 7, 8.	1.9	33
20	A polyphenol-rich prebiotic in combination with a novel probiotic formulation alleviates markers of obesity and diabetes in <i>Drosophila</i> . <i>Journal of Functional Foods</i> , 2018, 48, 374-386.	1.6	20
21	Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 3769-3787.	2.4	362
22	Design and validation of an orally administrated active <i>L. fermentum</i> - <i>L. acidophilus</i> probiotic formulation using colorectal cancer Apc Min/+ mouse model. <i>Applied Microbiology and Biotechnology</i> , 2017, 101, 1999-2019.	1.7	50
23	Effects of Simulated Human Gastrointestinal Digestion of Two Purple-Fleshed Potato Cultivars on Anthocyanin Composition and Cytotoxicity in Colonic Cancer and Non-Tumorigenic Cells. <i>Nutrients</i> , 2017, 9, 953.	1.7	35
24	Safety of transtympanic application of probiotics in a chinchilla animal model. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2017, 46, 63.	0.9	8
25	Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization. <i>Nanomaterials</i> , 2016, 6, 116.	1.9	113
26	Biotransformation of polyphenols in a dynamic multistage gastrointestinal model. <i>Food Chemistry</i> , 2016, 204, 453-462.	4.2	64
27	Dual-functionalized graphene oxide for enhanced siRNA delivery to breast cancer cells. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 147, 315-325.	2.5	49
28	Orally delivered microencapsulated probiotic formulation favorably impacts polyp formation in APC (Min/+) model of intestinal carcinogenesis. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2016, 44, 1-11.	1.9	31
29	Tailoring biomaterial surface properties to modulate host-implant interactions: implication in cardiovascular and bone therapy. <i>Journal of Materials Chemistry B</i> , 2016, 4, 1586-1599.	2.9	59
30	Biotransformation of anthocyanins from two purple-fleshed sweet potato accessions in a dynamic gastrointestinal system. <i>Food Chemistry</i> , 2016, 192, 171-177.	4.2	28
31	<i>Lactobacillus fermentum</i> NCIMB 5221 and NCIMB 2797 as cholesterol-lowering probiotic biotherapeutics: in vitro analysis. <i>Beneficial Microbes</i> , 2015, 6, 861-869.	1.0	17
32	A New Carbon Nanotube-Based Breast Cancer Drug Delivery System: Preparation and In Vitro Analysis Using Paclitaxel. <i>Cell Biochemistry and Biophysics</i> , 2015, 71, 1405-1414.	0.9	35
33	Nanomaterials and Cardiovascular Toxicity. , 2015, , 547-570.		0
34	Emerging science of the human microbiome. <i>Gut Microbes</i> , 2014, 5, 446-457.	4.3	46
35	Sustained release of milrinone delivered via microparticles in a rodent model of myocardial infarction. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 2316-2324.	0.4	17
36	Cholesterol Assimilation by <i>Lactobacillus</i> Probiotic Bacteria: An In Vitro Investigation. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	103

#	ARTICLE	IF	CITATIONS
37	The gut microbiome, probiotics, bile acids axis, and human health. Trends in Microbiology, 2014, 22, 306-308.	3.5	53
38	Bioengineered baculoviruses as new class of therapeutics using micro and nanotechnologies: Principles, prospects and challenges. Advanced Drug Delivery Reviews, 2014, 71, 115-130.	6.6	30
39	Effect of orally administered <i>L. fermentum</i> NCIMB 5221 on markers of metabolic syndrome: an in vivo analysis using ZDF rats. Applied Microbiology and Biotechnology, 2014, 98, 115-126.	1.7	57
40	Enrichment of <i>Bifidobacterium longum</i> subsp. <i>infantis</i> ATCC 15697 within the human gut microbiota using alginate-poly-L-lysine-alginate microencapsulation oral delivery system: an in vitro analysis using a computer-controlled dynamic human gastrointestinal model. Journal of Microencapsulation, 2014, 31, 230-238.	1.2	6
41	The human microbiome and bile acid metabolism: dysbiosis, dysmetabolism, disease and intervention. Expert Opinion on Biological Therapy, 2014, 14, 467-482.	1.4	116
42	Microencapsulated <i>Bifidobacterium longum</i> subsp. <i>infantis</i> ATCC 15697 Favorably Modulates Gut Microbiota and Reduces Circulating Endotoxins in F344 Rats. BioMed Research International, 2014, 2014, 1-11.	0.9	2,927
43	Investigation of probiotic bacteria as dental caries and periodontal disease biotherapeutics. Beneficial Microbes, 2014, 5, 447-460.	1.0	27
44	Intranasal Delivery of Chitosan-siRNA Nanoparticle Formulation to the Brain. Methods in Molecular Biology, 2014, 1141, 233-247.	0.4	12
45	Probiotics for the Prevention and Treatment of Allergies, with an Emphasis on Mode of Delivery and Mechanism of Action. Current Pharmaceutical Design, 2014, 20, 1025-1037.	0.9	26
46	Oral Supplementation With Probiotic <i>L. reuteri</i> NCIMB 30242 Increases Mean Circulating 25-Hydroxyvitamin D: A Post Hoc Analysis of a Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2944-2951.	1.8	134
47	Functional Assessment of Adipose Stem Cells for Xenotransplantation Using Myocardial Infarction Immunocompetent Models: Comparison with Bone Marrow Stem Cells. Cell Biochemistry and Biophysics, 2013, 67, 263-273.	0.9	53
48	Improvement of gastrointestinal health status in subjects consuming <i>Lactobacillus reuteri</i> NCIMB 30242 capsules: a post-hoc analysis of a randomized controlled trial. Expert Opinion on Biological Therapy, 2013, 13, 1643-1651.	1.4	10
49	Angiogenic Nanodelivery Systems for Myocardial Therapy. Methods in Molecular Biology, 2013, 1036, 137-149.	0.4	1
50	Design of a novel gut bacterial adhesion model for probiotic applications. Artificial Cells, Nanomedicine and Biotechnology, 2013, 41, 116-124.	1.9	9
51	Carbon nanotube lipid drug approach for targeted delivery of a chemotherapy drug in a human breast cancer xenograft animal model. Biomaterials, 2013, 34, 10109-10119.	5.7	91
52	Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials, 2013, 34, 1270-1280.	5.7	161
53	Probiotics in colorectal cancer (CRC) with emphasis on mechanisms of action and current perspectives. Journal of Medical Microbiology, 2013, 62, 1107-1123.	0.7	118
54	Recent advancements in tissue engineering for stem cell-based cardiac therapies. Therapeutic Delivery, 2013, 4, 503-516.	1.2	15

#	ARTICLE	IF	CITATIONS
55	Effect of Probiotics Lactobacillus and Bifidobacterium on Gut-Derived Lipopolysaccharides and Inflammatory Cytokines: An In Vitro Study Using a Human Colonic Microbiota Model. <i>Journal of Microbiology and Biotechnology</i> , 2013, 23, 518-526.	0.9	129
56	Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 631-642.	1.4	140
57	Novel probiotic dissolvable carboxymethyl cellulose films as oral health biotherapeutics: <i>in vitro</i> preparation and characterization. <i>Expert Opinion on Drug Delivery</i> , 2013, 10, 1471-1482.	2.4	36
58	Complements and the Wound Healing Cascade: An Updated Review. <i>Plastic Surgery International</i> , 2013, 2013, 1-7.	0.7	153
59	Topical application of complement C3 in collagen formulation increases early wound healing. <i>Journal of Dermatological Treatment</i> , 2013, 24, 141-147.	1.1	24
60	Complements C3 and C5 Individually and in Combination Increase Early Wound Strength in a Rat Model of Experimental Wound Healing. <i>Plastic Surgery International</i> , 2013, 2013, 1-5.	0.7	10
61	Letter to the editor regarding the report of Duboc <i>et al</i> : connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel disease. <i>Gut</i> , 2013, 62, 654-655.	6.1	14
62	Systemic siRNA Delivery via Peptide-Tagged Polymeric Nanoparticles, Targeting PLK1 Gene in a Mouse Xenograft Model of Colorectal Cancer. <i>International Journal of Biomaterials</i> , 2013, 2013, 1-13.	1.1	23
63	Bioactive baculovirus nanohybrids for stent based rapid vascular re-endothelialization. <i>Scientific Reports</i> , 2013, 3, 2366.	1.6	33
64	Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA. <i>International Journal of Nanomedicine</i> , 2013, 8, 2041.	3.3	60
65	Intranasal, siRNA Delivery to the Brain by TAT/MGF Tagged PEGylated Chitosan Nanoparticles. <i>Journal of Pharmaceutics</i> , 2013, 2013, 1-10.	4.6	20
66	Microencapsulation for the Therapeutic Delivery of Drugs, Live Mammalian and Bacterial Cells, and Other Biopharmaceutics: Current Status and Future Directions. <i>Journal of Pharmaceutics</i> , 2013, 2013, 1-19.	4.6	40
67	Route of Delivery, Cell Retention, and Efficiency of Polymeric Microcapsules in Cellular Cardiomyoplasty. <i>Methods in Molecular Biology</i> , 2013, 1036, 121-135.	0.4	4
68	Oral Probiotic Microcapsule Formulation Ameliorates Non-Alcoholic Fatty Liver Disease in Bio F1B Golden Syrian Hamsters. <i>PLoS ONE</i> , 2013, 8, e58394.	1.1	38
69	Cationic Albumin Nanoparticles for Enhanced Drug Delivery to Treat Breast Cancer: Preparation and <i>In Vitro</i> Assessment. <i>Journal of Drug Delivery</i> , 2012, 2012, 1-8.	2.5	86
70	Microencapsulated Mammalian Cells for Simultaneous Production of VEGF165b and IFN $\gamma$ . <i>Artificial Cells, Blood Substitutes, and Biotechnology</i> , 2012, 40, 1-6.	0.9	0
71	Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. <i>European Journal of Clinical Nutrition</i> , 2012, 66, 1234-1241.	1.3	212
72	Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. <i>British Journal of Nutrition</i> , 2012, 107, 1505-1513.	1.2	246

#	ARTICLE	IF	CITATIONS
73	Probiotic Ferulic Acid Esterase Active <i>Lactobacillus fermentum</i> NCIMB 5221 APA Microcapsules for Oral Delivery: Preparation and in Vitro Characterization. <i>Pharmaceuticals</i> , 2012, 5, 236-248.	1.7	53
74	Genipin-Cross-Linked Microencapsulated Human Adipose Stem Cells Augment Transplant Retention Resulting in Attenuation of Chronically Infarcted Rat Heart Fibrosis and Cardiac Dysfunction. <i>Cell Transplantation</i> , 2012, 21, 2735-2751.	1.2	33
75	<b>Probiotics as oral health biotherapeutics</b>. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1207-1220.	1.4	48
76	PAMAM Dendrimer-Baculovirus Nanocomplex for Microencapsulated Adipose Stem Cell-Gene Therapy: <i>In Vitro</i> and <i>in Vivo</i> Functional Assessment. <i>Molecular Pharmaceutics</i> , 2012, 9, 2479-2488.	2.3	29
77	Microencapsulated<i>Saccharomyces cerevisiae</i> Column Bioreactor for Potential Use in Renal Failure Uremia. <i>Artificial Cells, Blood Substitutes, and Biotechnology</i> , 2012, 40, 103-112.	0.9	1
78	Cellular cardiomyoplasty: current state of the field. <i>Regenerative Medicine</i> , 2012, 7, 571-582.	0.8	15
79	Prevention and Treatment of Virulent Bacterial Biofilms with an Enzymatic Nitric Oxide-Releasing Dressing. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6095-6103.	1.4	44
80	Evaluation of safety and tolerance of microencapsulated <i>Lactobacillus reuteri</i> NCIMB 30242 in a yogurt formulation: A randomized, placebo-controlled, double-blind study. <i>Food and Chemical Toxicology</i> , 2012, 50, 2216-2223.	1.8	45
81	The attenuation of restenosis following arterial gene transfer using carbon nanotube coated stent incorporating TAT/DNAAng1+Vegf nanoparticles. <i>Biomaterials</i> , 2012, 33, 7655-7664.	5.7	63
82	Nanomedicine in cardiovascular therapy: recent advancements. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 805-815.	0.6	34
83	Angiopietin-1-expressing adipose stem cells genetically modified with baculovirus nanocomplex: investigation in rat heart with acute infarction. <i>International Journal of Nanomedicine</i> , 2012, 7, 663.	3.3	25
84	Novel nitric oxide producing probiotic wound healing patch: preparation and in vivo analysis in a New Zealand white rabbit model of ischaemic and infected wounds. <i>International Wound Journal</i> , 2012, 9, 330-343.	1.3	58
85	Evaluation of clinical safety and tolerance of a <i>Lactobacillus reuteri</i> NCIMB 30242 supplement capsule: A randomized control trial. <i>Regulatory Toxicology and Pharmacology</i> , 2012, 63, 313-320.	1.3	54
86	Small interfering ribonucleic acid design strategies for effective targeting and gene silencing. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 269-289.	2.5	14
87	Current developments in the tissue engineering of autologous heart valves: moving towards clinical use. <i>Future Cardiology</i> , 2011, 7, 77-97.	0.5	27
88	A novel method for synthesizing PEGylated chitosan nanoparticles: strategy, preparation, and in vitro analysis. <i>International Journal of Nanomedicine</i> , 2011, 6, 485.	3.3	61
89	Diet-induced metabolic hamster model of nonalcoholic fatty liver disease. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2011, 4, 195.	1.1	22
90	Gut microbiota: next frontier in understanding human health and development of biotherapeutics. <i>Biologics: Targets and Therapy</i> , 2011, 5, 71.	3.0	181

#	ARTICLE	IF	CITATIONS
91	Superior Therapeutic Potential of Young Bone Marrow Mesenchymal Stem Cells by Direct Intramyocardial Delivery in Aged Recipients with Acute Myocardial Infarction: In Vitro and In Vivo Investigation. <i>Journal of Tissue Engineering</i> , 2011, 2011, 741213.	2.3	20
92	A nanobiohybrid complex of recombinant baculovirus and Tat/DNA nanoparticles for delivery of Ang-1 transgene in myocardial infarction therapy. <i>Biomaterials</i> , 2011, 32, 8304-8318.	5.7	51
93	Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 1340-1351.	6.6	226
94	Investigation of siRNA-Loaded Polyethylenimine-Coated Human Serum Albumin Nanoparticle Complexes for the Treatment of Breast Cancer. <i>Cell Biochemistry and Biophysics</i> , 2011, 61, 277-287.	0.9	45
95	Superior Cell Delivery Features of Genipin Crosslinked Polymeric Microcapsules: Preparation, In Vitro Characterization and Pro-Angiogenic Applications Using Human Adipose Stem Cells. <i>Molecular Biotechnology</i> , 2011, 48, 116-127.	1.3	31
96	Microencapsulation to reduce mechanical loss of microspheres: implications in myocardial cell therapy. <i>European Journal of Cardio-thoracic Surgery</i> , 2011, 39, 241-247.	0.6	47
97	Bone Marrow Stem Cell Derived Paracrine Factors for Regenerative Medicine: Current Perspectives and Therapeutic Potential. <i>Bone Marrow Research</i> , 2011, 2011, 1-14.	1.7	124
98	The Gut Microbiota and Human Health with an Emphasis on the Use of Microencapsulated Bacterial Cells. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-12.	3.0	71
99	Transit Time Affects the Community Stability of <i>Lactobacillus</i> and <i>Bifidobacterium</i> Species in an In Vitro Model of Human Colonic Microbiota. <i>Artificial Cells, Blood Substitutes, and Biotechnology</i> , 2011, 39, 351-356.	0.9	22
100	A novel nitric oxide producing probiotic patch and its antimicrobial efficacy: preparation and in vitro analysis. <i>Applied Microbiology and Biotechnology</i> , 2010, 87, 509-516.	1.7	55
101	Antimicrobial properties of nitric oxide and its application in antimicrobial formulations and medical devices. <i>Applied Microbiology and Biotechnology</i> , 2010, 88, 401-407.	1.7	158
102	Investigation on PEG Integrated Alginate-Chitosan Microcapsules for Myocardial Therapy Using Marrow Stem Cells Genetically Modified by Recombinant Baculovirus. <i>Cardiovascular Engineering and Technology</i> , 2010, 1, 154-164.	0.7	23
103	Recombinant Baculovirus as a Highly Potent Vector for Gene Therapy of Human Colorectal Carcinoma: Molecular Cloning, Expression, and In Vitro Characterization. <i>Molecular Biotechnology</i> , 2010, 45, 129-139.	1.3	18
104	Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. <i>International Journal of Nanomedicine</i> , 2010, 5, 525.	3.3	112
105	Investigation of Genipin Cross-Linked Microcapsule for Oral Delivery of Live Bacterial Cells and Other Biotherapeutics: Preparation and In Vitro Analysis in Simulated Human Gastrointestinal Model. <i>International Journal of Polymer Science</i> , 2010, 2010, 1-10.	1.2	10
106	Baculovirus reveals a new pH-dependent direct cell-fusion pathway for cell entry and transgene delivery. <i>Future Virology</i> , 2010, 5, 533-537.	0.9	7
107	Suppression of Tumorigenesis: Modulation of Inflammatory Cytokines by Oral Administration of Microencapsulated Probiotic Yogurt Formulation. <i>International Journal of Inflammation</i> , 2010, 2010, 1-10.	0.9	22
108	BacMam Virus Transduced Cardiomyoblasts Can Be Used for Myocardial Transplantation Using AP-PEG-A Microcapsules: Molecular Cloning, Preparation, and In Vitro Analysis. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-12.	3.0	4



#	ARTICLE	IF	CITATIONS
109	Investigation of Antiangiogenic Tumor Therapy Potential of Microencapsulated HEK293 VEGF<sub>165</sub> Producing Cells. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-7.	3.0	9
110	Nano- and Biotechnological Approaches in Current and Future Generation of Cardiovascular Stents. Current Nanoscience, 2010, 6, 469-478.	0.7	8
111	Nanoscaffold based stem cell regeneration therapy: recent advancement and future potential. Expert Opinion on Biological Therapy, 2010, 10, 1649-1661.	1.4	27
112	Genipin Cross-Linked Polymeric Alginate-Chitosan Microcapsules for Oral Delivery: In-Vitro Analysis. International Journal of Polymer Science, 2009, 2009, 1-16.	1.2	26
113	Orally Delivered Microencapsulated Live Probiotic Formulation Lowers Serum Lipids in Hypercholesterolemic Hamsters. Journal of Medicinal Food, 2009, 12, 310-319.	0.8	55
114	Nonviral Production of Human Interleukin-7 in Spodoptera Frugiperda Insect Cells as a Soluble Recombinant Protein. Journal of Biomedicine and Biotechnology, 2009, 2009, 1-8.	3.0	8
115	Estimation of the Potential Antitumor Activity of Microencapsulated Lactobacillus acidophilus Yogurt Formulation in the Attenuation of Tumorigenesis in Apc(Min/+) Mice. Digestive Diseases and Sciences, 2009, 54, 264-273.	1.1	68
116	Microcapsule carbon nanotube devices for therapeutic applications. Nanotechnology, 2009, 20, 025612.	1.3	18
117	Microencapsulated stem cells for tissue repairing: implications in cell-based myocardial therapy. Regenerative Medicine, 2009, 4, 733-745.	0.8	56
118	Ultrafine chitosan nanoparticles as an efficient nucleic acid delivery system targeting neuronal cells. Drug Development and Industrial Pharmacy, 2009, 35, 719-726.	0.9	41
119	Potentials and limitations of microorganisms as renal failure biotherapeutics. Biologics: Targets and Therapy, 2009, 3, 233-43.	3.0	4
120	Microencapsulated bile salt hydrolase producing Lactobacillus reuteri for oral targeted delivery in the gastrointestinal tract. Applied Microbiology and Biotechnology, 2008, 81, 225-233.	1.7	39
121	Expression and Production of Human Interleukin-7 in Insect Cells Using Baculovirus Expression Vector System (BEVS). Applied Biochemistry and Biotechnology, 2008, 151, 93-103.	1.4	11
122	Preparation and <i>in vitro</i> analysis of microencapsulated live Lactobacillus fermentum 11976 for augmentation of feruloyl esterase in the gastrointestinal tract. Biotechnology and Applied Biochemistry, 2008, 50, 1-9.	1.4	23
123	<i>In vitro</i> cytotoxicity of functionalized single walled carbon nanotubes for targeted gene delivery applications. Nanotoxicology, 2008, 2, 184-188.	1.6	16
124	Expression of SEAP (secreted alkaline phosphatase) by baculovirus mediated transduction of HEK 293 cells in a hollow fiber bioreactor system. Journal of Biotechnology, 2008, 135, 272-280.	1.9	33
125	Live immobilised cells as new therapeutics. Journal of Drug Delivery Science and Technology, 2008, 18, 3-14.	1.4	3
126	Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells. Biologics: Targets and Therapy, 2008, 2, 355.	3.0	8



#	ARTICLE	IF	CITATIONS
127	Impact of Orally Administered Microcapsules on Gastrointestinal Microbial Flora: In-Vitro Investigation Using Computer Controlled Dynamic Human Gastrointestinal Model. <i>Artificial Cells, Blood Substitutes, and Biotechnology</i> , 2007, 35, 359-375.	0.9	7
128	Introduction to artificial cells: concept, history, design, current status and future. , 2007, , 3-41.		0
129	Recent Advances in Drug Delivery: Potential and Limitations of Carbon Nanotubes. <i>Recent Patents on Drug Delivery and Formulation</i> , 2007, 1, 214-221.	2.1	26
130	Inflammatory bowel diseases: current treatment strategies and potential for drug delivery using artificial cell microcapsules. , 2007, , 454-468.		1
131	Live encapsulated <i>Lactobacillus acidophilus</i> cells in yogurt for therapeutic oral delivery: preparation and in vitro analysis of alginate-chitosan microcapsules This article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products.. <i>Canadian Journal of Physiology and Pharmacology</i> . 2007. 85. 884-893.	0.7	45
132	Investigation of Microencapsulated BSH Active <i>Lactobacillus</i> in the Simulated Human GI Tract. <i>Journal of Biomedicine and Biotechnology</i> , 2007, 2007, 1-9.	3.0	32
133	Preparation and characterization of novel polymeric microcapsules for live cell encapsulation and therapy. <i>Cell Biochemistry and Biophysics</i> , 2007, 47, 159-167.	0.9	47
134	Microencapsulated bacterial cells can be used to produce the enzyme feruloyl esterase: preparation and in-vitro analysis. <i>Applied Microbiology and Biotechnology</i> , 2007, 75, 1023-1029.	1.7	30
135	Microencapsulated Engineered <i>Lactococcus lactis</i> Cells for Heterologous Protein Delivery: Preparation and In Vitro Analysis. <i>Applied Biochemistry and Biotechnology</i> , 2007, 142, 71-80.	1.4	5
136	Genipin Cross-Linked Alginate-Chitosan Microcapsules: Membrane Characterization and Optimization of Cross-Linking Reaction. <i>Biomacromolecules</i> , 2006, 7, 2091-2098.	2.6	89
137	Toward a New Generation of Therapeutics: Artificial Cell Targeted Delivery of Live Cells for Therapy. <i>Applied Biochemistry and Biotechnology</i> , 2006, 128, 001-022.	1.4	32
138	A New Method for Microcapsule Characterization: Use of Fluorogenic Genipin to Characterize Polymeric Microcapsule Membranes. <i>Applied Biochemistry and Biotechnology</i> , 2006, 134, 207-222.	1.4	8
139	A New Method for Targeted Drug Delivery Using Polymeric Microcapsules: Implications for Treatment of Crohn's Disease. <i>Cell Biochemistry and Biophysics</i> , 2005, 43, 077-086.	0.9	10
140	Reaction of chitosan with genipin and its fluorogenic attributes for potential microcapsule membrane characterization. <i>Journal of Biomedical Materials Research - Part A</i> , 2005, 75A, 917-927.	2.1	83
141	In vitro study of alginate-chitosan microcapsules: an alternative to liver cell transplants for the treatment of liver failure. <i>Biotechnology Letters</i> , 2005, 27, 317-322.	1.1	88
142	Artificial Cell Therapy: New Strategies for the Therapeutic Delivery of Live Bacteria. <i>Journal of Biomedicine and Biotechnology</i> , 2005, 2005, 44-56.	3.0	63
143	Investigation of a New Microcapsule Membrane Combining Alginate, Chitosan, Polyethylene Glycol and Poly-L-Lysine for Cell Transplantation Applications. <i>International Journal of Artificial Organs</i> , 2005, 28, 631-637.	0.7	36
144	In-vitro analysis of APA microcapsules for oral delivery of live bacterial cells. <i>Journal of Microencapsulation</i> , 2005, 22, 539-547.	1.2	32

#	ARTICLE	IF	CITATIONS
145	Live bacterial cells as orally delivered therapeutics. Expert Opinion on Biological Therapy, 2005, 5, 1281-1301.	1.4	10
146	Superior Cell Delivery Features of Poly(ethylene glycol) Incorporated Alginate, Chitosan, and Poly-l-lysine Microcapsules. Molecular Pharmaceutics, 2005, 2, 29-36.	2.3	81
147	Microencapsulated Genetically Engineered Lactobacillus plantarum 80 (pCBH1) for Bile Acid Deconjugation and Its Implication in Lowering Cholesterol. Journal of Biomedicine and Biotechnology, 2004, 2004, 61-69.	3.0	76
148	Artificial cell microcapsule for oral delivery of live bacterial cells for therapy: design, preparation, and in-vitro characterization. Journal of Pharmacy and Pharmaceutical Sciences, 2004, 7, 315-24.	0.9	31
149	Free and Microencapsulated Lactobacillus and Effects of Metabolic Induction on Urea Removal. Artificial Cells, Blood Substitutes, and Biotechnology, 2003, 31, 425-434.	0.9	30
150	Procedures for Microencapsulation of Enzymes, Cells and Genetically Engineered Microorganisms. Molecular Biotechnology, 2001, 17, 249-260.	1.3	71
151	In vitro and in vivo Uric Acid Lowering by Artificial Cells Containing Microencapsulated Genetically Engineered E. coli DH5 Cells. International Journal of Artificial Organs, 2000, 23, 429-435.	0.7	37
152	Artificial Cells Microencapsulated Genetically Engineered E. Coli DH 5 Cells for the Lowering of Plasma Creatinine In-Vitro and In-Vivo. Artificial Cells, Blood Substitutes, and Biotechnology, 2000, 28, 397-408.	0.9	15
153	In vitro and in vivo uric acid lowering by artificial cells containing microencapsulated genetically engineered E. coli DH5 cells. International Journal of Artificial Organs, 2000, 23, 429-35.	0.7	11
154	Artificial Cell Microcapsules Containing Genetically Engineered E. Coli dh5 Cells for In-Vitro Lowering of Plasma Potassium, Phosphate, Magnesium, Sodium, Chloride, Uric Acid, Cholesterol, And Creatinine : A Preliminary Report. Artificial Cells, Blood Substitutes, and Biotechnology, 1999, 27, 475-481.	0.9	16
155	Growth Kinetics of Genetically Engineered E. Coli dh5 Cells in Artificial Cell Apa Membrane Microcapsules: Preliminary Report. Artificial Cells, Blood Substitutes, and Biotechnology, 1999, 27, 291-301.	0.9	10
156	Therapeutic uses of microencapsulated genetically engineered cells. Trends in Molecular Medicine, 1998, 4, 221-227.	2.6	103
157	Growth and Survival of Renal Failure Rats that Received Oral Microencapsulated Genetically Engineered E. Coli Dh5 Cells for Urea Removal. Artificial Cells, Blood Substitutes, and Biotechnology, 1998, 26, 35-51.	0.9	16
158	Artificial Cells for Bioencapsulation of Cells and Genetically Engineered E. coli: For Cell Therapy, Gene Therapy, and Removal of Urea and Ammonia. , 1997, 63, 343-358.		16
159	Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nature Medicine, 1996, 2, 883-887.	15.2	204
160	Microencapsulated genetically engineered E. coli DH5 cells for plasma urea and ammonia removal based on: 1. Column bioreactor and 2. Oral administration in uremic rats. Artificial Cells, Blood Substitutes, and Biotechnology, 1996, 24, 201-218.	0.9	12
161	Preparation and in vitro analysis of microencapsulated genetically engineered E. coli DH5 cells for urea and ammonia removal. Biotechnology and Bioengineering, 1995, 46, 621-626.	1.7	61
162	Genetically Engineered E. COLI Cells Containing K. AEROGENES Gene, Microencapsulated in Artificial Cells for Urea and Ammonia Removal. Biomaterials, Artificial Cells, and Immobilization Biotechnology: Official Journal of the International Society for Artificial Cells and Immobilization Biotechnology, 1993, 21, 629-636.	0.2	10

#	ARTICLE	IF	CITATIONS
163	Artificial cells containing genetically engineered E. coli DH5 cells for urea and ammonia removal in kidney and liver failure. , 0 , , .		0
164	Carbon Nanotubes for Use in Medicine: Potentials and Limitations. , 0 , , .		19